Numerous advocacy organizations are sounding the alarm over a recent HHS notice that restricts access to federal benefits for ...

A group of Democratic attorneys general filed a lawsuit against HHS and CMS, arguing that their recent final rule will harm access to care under the Affordable Care Act.

Sarepta Therapeutics knew about the death of a patient treated with its experimental gene therapy for a type of limb-girdle muscular dystrophy, but said nothing publicly for a month. Financial ...

Most patients are open to the use of AI in healthcare — as long as it enhances, rather than replaces, human interaction, according to new research. It also showed that patients want transparency ...

Sarepta’s Elevidys will remain on the market with a black box warning. But this gene therapy for Duchenne muscular dystrophy still faces commercial headwinds and analysts say the company has ...

Healthcare providers are making cybersecurity progress, but serious vulnerabilities remain — especially when it comes to AI ...

Hengrui’s peptide drug, HRS9531, is engineered to bind to and activate the GLP-1 and GIP receptors — the same two targets hit by blockbuster Eli Lilly’s chronic weight management drug ...

A bill introduced by Rep. Earl L. "Buddy" Carter would ban PBMs’ use of spread pricing in Medicaid, among other reforms.

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

Hospital M&A activity slowed quite a bit in the first half of 2025, with deal volume and transacted revenue falling sharply amid economic uncertainty and sweeping policy changes. While traditional ...